PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI
Key facts
- Who runs it
- Maastricht Radiation Oncology
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 67 people, planned
- Started
- 8 Apr 2021
- Expected to end
- 1 May 2029
- Type of study
- Observational
- Treatments tested
- PRECODE-MRI
- Record updated
- 7 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Meningioma WHO I, grading based on pathology or radiological features
- Age ≥ 18 years
- Karnofsky Performance Score 70 or above
- Ability to comply with the protocol, including neuropsychological testing and imaging
- Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician
- Written informed consent
Who cannot take part
- Resection meningioma < 3mnd
- Any prior cranial radiotherapy
- Any prior chemotherapy in the last 5 years
- Contra-indication for MR imaging (i.e. metal implants, claustrophobia)
- Any other serious medical condition that could interfere with follow-up
- Age < 18 years
- Pregnancy
- Severe aphasia or language barrier interfering with assessing endpoints (i.e. completion of questionnaires or neurocognitive performance)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Meningioma are slow growing and frequently occurring intracranial tumors, responsible for 33% of all asymptomatic intracranial tumors and 13-26% of all symptomatic primary brain tumors. The 10-year survival rate is 72%. A variety of treatment options is available for symptomatic meningioma including surgical removal with or without radiotherapy or radiotherapy alone. These therapies can have negative impact on cerebral functioning.
Read full original descriptionShow less
After high dose radiotherapy for primary or metastatic brain tumors 50-90% of > 6 months' survivors develop irreversible disabling cognitive decline leading to premature loss of independence, reduced Quality of Life (QOL) as well as significant economic burden both at the individual as societal level. Especially for patients with a good prognosis like benign meningioma, maintaining neurocognitive function is crucial. Understanding the mechanisms underlying radiation induced cognitive decline is complex and which brain areas to spare are an important subject of research.
Evaluation methods to assess cognitive function and predict cognitive decline are urgently needed, this will allow the development of optimized treatment strategies with the aim to preserve or even improve cognitive function in meningioma patients. Improvements in the field of neuroimaging techniques (i.e. advanced MRI techniques) have the possibility to identify areas susceptible to cognitive impairment. This allows in the future a more personalized radiation treatment by identifying patients at risk, by optimizing the radiotherapy dose to specific brain regions, that could eventually reduce or prevent, cognitive decline. Improvements in the field of radiotherapy for example by higher precision treatment such proton therapy have potential in obtaining these more individualized strategies.
Treatments tested
- PRECODE-MRI
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 7 July 2026